资料单张
QUINAGLUTE DURA-TABS
SCHEDULING STATUS:
S2
PROPRIETARY NAME
(and dosage form):
QUINAGLUTE DURA-TABS
Tablets
COMPOSITION
Each tablet contains
quinidine gluconate
324 mg in a tablet matrix specially designed for the prolonged (8 or 12 hour
interval) release of the medicine in the gastro-intestinal tract.
Quinidine gluconate contains 62,3% of the anhydrous quinidine alkaloid, whereas quinidine sulphate contains 82,86%.
In prescribing Quinaglute Dura-Tabs, this factor should be considered.
PHARMACOLOGICAL CLASSIFICATION
A. 6.2 Cardiac depressants.
PHARMACOLOGICAL ACTION
The antiarrhythmic activity of quinidine consists of two basic actions: (a) prolongation of effective refractory period of
the atrial or ventricular muscle which leads to termination of arrhythmia; (b) decrease in excitability of ectopic foci of the
heart. The action is not limited to these two properties on the heart. In addition, quinidine (c) blocks vagal innervation
and (d) facilitates conduction in the atrioventricular junction. In the treatment of cardiac arrhythmia, quinidine is
administered in a dose that will exert actions (a) and (b) with a minimal effect on (c) and (d).
INDICATIONS
For the prevention of premature atrial, nodal or ventricular contractions. For maintenance of normal sinus rhythm
following conversion by other techniques of atrial, nodal or ventricular tachycardia, atrial flutter and fibrillation
(paroxysmal or chronic).
CONTRA-INDICATIONS
Aberrant impulses and abnormal rhythms due to escape mechanisms should not be treated with quinidine.
Partial A-V or complete heart block, or intraventricular conduction defects, especially those exhibiting a marked grade of
QRS widening.
Renal disease resulting in significant azotemia, or those developing cardiotoxic effects such as conduction defects,
ventricular premat
阅读完整的文件
资料单张 